177Lu-J591

DRUG4 trials

Sponsors

Weill Medical College of Cornell University

Conditions

Breast CancerColorectal CancerEsophageal CancerGliomasHead and Neck CancerKidney CancerNon-small Cell Lung CancerOvarian Cancer

Phase 1

Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer

CompletedNCT00916123

Weill Medical College of Cornell UniversityProstate Cancer

Start: 2009-05-31End: 2018-12-31Updated: 2021-05-20

177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors

CompletedNCT00967577

Weill Medical College of Cornell UniversityBreast Cancer, Colorectal Cancer, Esophageal Cancer +6

Start: 2009-07-31End: 2021-12-31Updated: 2022-02-02

177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC

TerminatedNCT03545165

Weill Medical College of Cornell UniversityProstate Cancer

Start: 2018-04-18End: 2020-07-15Updated: 2021-08-24

Phase 2

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

Active, not recruitingNCT00859781

Weill Medical College of Cornell UniversityProstate Cancer

Start: 2009-06-01End: 2026-09-01Updated: 2026-04-08

Related Papers

Updated follow up of a randomized, double-blinded phase II study of ketoconazole (keto), hydrocortisone (HC), and anti-PSMA antibody J591 labeled with 177Lu or 111In in patients (pts) with high-risk non-metastatic (met) castration-resistant prostate cancer (M0 CRPC).

Journal of Clinical Oncology2025-02-102 citations

Randomized, double-blinded phase II study of ketoconazole (keto), hydrocortisone (HC), and anti-PSMA antibody J591 labeled with <sup>177</sup>Lu or <sup>111</sup>In in patients (pts) with high-risk non-metastatic (met) castration-resistant prostate cancer (M0 CRPC).

Journal of Clinical Oncology2023-02-206 citations

Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (<sup>177</sup>Lu-J591) for metastatic castration-resistant prostate cancer.

2020-06-2734 citations

Association of noninvasive, radiographic measurement of prostate-specific membrane antigen (PSMA) expression with response to PSMA-targeted radionuclide therapy (TRT).

Journal of Clinical Oncology2019-05-202 citations

Phase I/II dose-escalation trial of fractionated dose <sup>177</sup>Lu-J591 plus <sup>177</sup>Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2019-03-011 citations

Fractionated dose radiolabeled antiprostate specific membrane antigen (PSMA) radioimmunotherapy (<sup>177</sup>Lu-J591) with or without docetaxel for metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2015-03-013 citations

Effect of prostate-specific membrane antigen (PSMA) radioimmunotherapy on circulating tumor cell (CTC) count.

Journal of Clinical Oncology2015-03-01

Phase I trial of docetaxel/prednisone plus fractionated dose radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody <sup>177</sup>lu-J591 in patients with metastatic, castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2014-05-209 citations